HGFK1 is Associated with a Better Prognostis and Reverses Inhibition by Gefitinib in NSCLC Cases |
Zhou, Xiao-Hui
(Department of Respiratory Medicine, the First Affiliated Hospital of Soochow University)
Tang, Li-Na (Department of Oncology, Shanghai 6th People's Hospital, Shanghai Jiao Tong University) Yue, Lu (Cancer Center, the Medical School, Hospital of Qingdao University) Min, Da-Liu (Department of Oncology, Shanghai 6th People's Hospital, Shanghai Jiao Tong University) Yang, Yi (Department of Thoracic Surgery, Shanghai 6th People's Hospital, Shanghai Jiao Tong University) Huang, Jian-An (Department of Respiratory Medicine, the First Affiliated Hospital of Soochow University) Shen, Zan (Department of Oncology, Shanghai 6th People's Hospital, Shanghai Jiao Tong University) |
1 | Bell DW, Lynch TJ, Haserlat SM, et al (2005). Epidermal growth factor receptor mutations and gene amplification in nonsmall- cell lung cancer: molecular analysis of the IDEAL/ INTACT gefitinib trials. J Clin Oncol, 23, 8081-92. DOI |
2 | Cappuzzo F, Hirsch FR, Rossi E, et al (2005). Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst, 97, 643-55. DOI |
3 | Chorostowska-Wynimko J, Szpechcinski A (2007). The impact of genetic markers on the diagnosis of lung cancer: a current perspective. J Thorac Oncol, 2, 1044-51. DOI |
4 | Ciardiello F, Tortora G (2008). EGFR antagonists in cancer treatment. N Engl J Med, 358, 1160-74. DOI |
5 | Engelman JA, Zejnullahu K, Mitsudomi T, et al (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 316, 1039-43. DOI ScienceOn |
6 | Fukuoka M, Yano S, Giaccone G, et al (2003). Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol, 21, 2237-46. DOI ScienceOn |
7 | Gschwind A, Fischer OM, Ullrich A (2004). The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer, 4, 361-70. DOI |
8 | Guo R, Chen X, Wang T, et al (2011). Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer. BMC Cancer, 11, 90. DOI ScienceOn |
9 | Hynes NE, Lane HA (2005). ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer, 5, 341-54. DOI ScienceOn |
10 | Kim ES, Hirsh V, Mok T, et al (2008). Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet, 372, 1809-18. DOI ScienceOn |
11 | Kosaka T, Yamaki E, Mogi A, et al (2011). Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer. J Biomed Biotechnol, 2011, 165214. |
12 | Kris MG, Natale RB, Herbst RS, et al (2003). Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA, 290, 2149-58. DOI ScienceOn |
13 | Li D, Ambrogio L, Shimamura T, et al (2008). BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene, 27, 4702-11. DOI ScienceOn |
14 | Lynch TJ, Bell DW, Sordella R, et al (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 350, 2129-39. DOI ScienceOn |
15 | Mahata S, Bharti AC, Shukla S, et al (2011). Berberine modulates AP-1 activity to suppress HPV transcription and downstream signaling to induce growth arrest and apoptosis in cervical cancer cells. Mol Cancer, 10, 39. DOI |
16 | Moyer JD, Barbacci EG, Iwata KK, et al (1997). Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res, 57, 4838-48. |
17 | Nie B, Shen Z, Wen JB, et al (2008). AAV-HGFK1 and Ad-p53 cocktail therapy prolongs survival of mice with colon cancer. Mol Cancer Ther, 7, 2855-65. DOI |
18 | Pao W, Miller V, Zakowski M, et al (2004). EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A, 101, 13306-11. DOI ScienceOn |
19 | Nishimura Y, Yoshioka K, Bereczky B, et al (2008). Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line. Mol Cancer, 7, 42. DOI |
20 | Paez JG, Janne PA, Lee JC, et al (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304, 1497-500. DOI ScienceOn |
21 | Perez-Soler R, Chachoua A, Hammond LA, et al (2004). Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol, 22, 3238-47. DOI ScienceOn |
22 | Sharma SV, Bell DW, Settleman J, et al (2007). Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer, 7, 169-81. DOI ScienceOn |
23 | Shen Z, Wong OG, Yao RY, et al (2008a). A novel and effective hepatocyte growth factor kringle 1 domain and p53 cocktail viral gene therapy for the treatment of hepatocellular carcinoma. Cancer Lett, 272, 268-76. DOI |
24 | Shen Z, Yang ZF, Gao Y, et al (2008b). The kringle 1 domain of hepatocyte growth factor has antiangiogenic and antitumor cell effects on hepatocellular carcinoma. Cancer Res, 68, 404-14. DOI |
25 | Tang Z, Du R, Jiang S, et al (2008). Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer, 99, 911-22. DOI ScienceOn |
26 | Xin L, Xu R, Zhang Q, et al (2000). Kringle 1 of human hepatocyte growth factor inhibits bovine aortic endothelial cell proliferation stimulated by basic fibroblast growth factor and causes cell apoptosis. Biochem Biophys Res Commun, 277, 186-90. DOI |
27 | Tsao MS, Sakurada A, Cutz JC, et al (2005). Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med, 353, 133-44. DOI ScienceOn |